Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Its proprietary clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company?s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates, including Binimetinib, an MEK inhibitor for cancer; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company?s partnered clinical program
|Shares Outstanding||EPS||-0.71||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||9.82%||Sales Growth - Q/Q||-75.48%||P/E||-10.59|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-2.94%||ROE||-12.23%||ROI||-3.87%|
|Current Ratio||4.38||Quick Ratio||Long Term Debt/Equity||0.71||Debt Ratio||0.9|
|Gross Margin||-7.14%||Operating Margin||-5.45%||Net Profit Margin||-13.45%||Dividend Payout Ratio|
|Cash From Financing Activities||38.85 M||Cash From Investing Activities||12.56 M||Cash From Operating Activities||21.47 M||Gross Profit||-5.54 M|
|Net Profit||58.31 M||Operating Profit||54.47 M||Total Assets||208.44 M||Total Current Assets||196.59 M|
|Total Current Liabilities||44.92 M||Total Debt||107.98 M||Total Liabilities||158.29 M||Total Revenue||6.6 M|
|High 52 week||24.85||Low 52 week||12.92||Last close||21.86||Last change||0.14%|
|RSI||40.1||Average true range||0.88||Beta||1.32||Volume||2.74 M|
|Simple moving average 20 days||-2.41%||Simple moving average 50 days||-5.74%||Simple moving average 200 days||20.64%|
|Performance Week||0.28%||Performance Month||-2.19%||Performance Quart||-5.49%||Performance Half||48.61%|
|Performance Year||40.58%||Performance Year-to-date||53.4%||Volatility daily||2.13%||Volatility weekly||4.77%|
|Volatility monthly||9.78%||Volatility yearly||33.87%||Relative Volume||178.42%||Average Volume||2.54 M|
|New High||0.46%||New Low|
2019-07-31 05:01:52 | Here’s How Pfizer Stock and Pharma Stand to Benefit From Mylan Deal
2019-07-29 11:40:59 | Pfizer PFE Beats on Q2 Earnings, to Merge Upjohn With Mylan
2019-07-29 10:12:02 | What's in Store for Array BioPharma ARRY in Q4 Earnings?
2019-07-29 08:56:00 | Pfizer stock down after revenue miss, merger announcement
2019-07-26 12:06:04 | What's in the Cards for Pfizer PFE This Earnings Season?
2019-07-26 09:55:00 | Array Acquisition Could Be a Huge Win for Pfizer, Analyst Says
2019-07-25 09:00:01 | Array BioPharma ARRY Moves to Buy: Rationale Behind the Upgrade
2019-07-10 10:35:00 | Rigrodsky & Long, P.A. Files Class Action Suit Against Array BioPharma Inc.
2019-07-10 09:25:00 | Here's Why Blueprint Medicines Stock Rose 75% in the First Half of 2019
2019-07-10 08:19:00 | Here's Why Array BioPharma Soared 75.4% in June
2019-07-08 22:18:09 | Legal Investigation Alert: Halper Sadeh LLP Continues Investigating Whether the Sale of Array BioPharma Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARRY
2019-07-08 11:43:00 | Pfizer Looks Pretty Smart With Array BioPharma Purchase. Here’s Why.
2019-07-06 05:19:00 | Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
2019-07-02 15:38:28 | 3 Dow Jones Stocks to Buy for the Second Half
2019-06-28 11:05:03 | Should First Trust Mid Cap Growth AlphaDEX Fund FNY Be on Your Investing Radar?
2019-06-27 12:01:00 | Lifshitz & Miller LLP Announces Investigation of Array BioPharma Inc., C&J Energy Services, Inc., Liberty Expedia Holdings, Inc., and Raytheon Company, Shutterfly, Inc., Sotheby's and Stewardship Financial Corporation, and Zimmer Biomet Holdings, Inc.
2019-06-25 10:32:02 | Abbvie Decides to Acquire Allergan
2019-06-25 10:14:02 | AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20
2019-06-25 08:00:00 | Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
2019-06-24 16:23:08 | Why These Innovative Biotech ETFs Soaring
2019-06-24 11:45:24 | Eldorado to Buy Caesars
2019-06-24 10:06:02 | U.S. Senate Takes on Big Tech, Plus "Merger Monday"
2019-06-23 09:00:00 | These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?
2019-06-21 15:12:00 | Oh, By the Way, This Clinical Trial Didn't Work
2019-06-21 10:01:02 | 3 Big Biotechs Hold Growth Potential in Second Half of 2019
2019-06-21 09:40:01 | Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma
2019-06-20 10:38:59 | Is Pfizer Overpaying for Array Biopharma?
2019-06-19 16:49:14 | Here's Pfizer's Motivation Behind Its Biggest Takeover In 3 Years
2019-06-19 11:20:03 | Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
2019-06-19 09:27:36 | A Beloved Biotech ETF Could Lure Traders Again
2019-06-19 09:06:01 | Big Drugmakers That May Tread the M&A Path After Pfizer
2019-06-18 17:57:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition
2019-06-18 15:51:00 | Papa John’s Auditor Swap Is Not a Good Look
2019-06-18 09:55:01 | Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
2019-06-18 09:51:14 | Cancer Therapy Stocks Soar After Pfizer Deal
2019-06-18 09:51:01 | Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio
2019-06-18 09:35:01 | Company News For Jun 18, 2019
2019-06-18 08:04:37 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-06-18 02:07:40 | PRESS DIGEST - Wall Street Journal - June 18
2019-06-17 18:14:10 | Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Array BioPharma Inc. NASDAQ: ARRY on Behalf of Array Shareholders and Encourages Array Investors to Contact the Firm
2019-06-17 17:06:21 | What Happened in the Stock Market Today
2019-06-17 17:00:00 | Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon
2019-06-17 16:48:37 | How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers
2019-06-17 16:41:29 | Dow Jones Today: Almost a Case of the Mondays
2019-06-17 16:23:03 | Pfizer acquires Array in 2nd major Boulder bioscience merger this month
2019-06-17 16:05:26 | 5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA